Examination of some factors responsible for a food-induced increase in absorption of atovaquone.
about
Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosisLC-APCI mass spectrometric method development and validation for the determination of atovaquone in human plasma.Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria.Effects of a high-fat meal on the relative oral bioavailability of piperaquineAntiparasitic agent atovaquoneClinical studies with oral lipid based formulations of poorly soluble compoundsAntimalarial pharmacology and therapeutics of atovaquoneA small amount of fat does not affect piperaquine exposure in patients with malaria.Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects?The effects of serum lipids on the in vitro activity of lumefantrine and atovaquone against Plasmodium falciparum.Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.Effect of Khat (Catha edulis) Use on the Bioavailability, Plasma Levels and Antimalarial Activity of Chloroquine.Assessment of safety of the major antimalarial drugs.Influence of Food on Paediatric Gastrointestinal Drug Absorption Following Oral Administration: A Review.Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis.Outbreak of Pneumocystis jirovecii Infection among Heart Transplant Recipients: Molecular Investigation and Management of an Inter-human Transmission.Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients.Disposition of atovaquone in humans.Effects of dietary fat on drug absorption.A validated method for development of atovaquone as API and tablet dosage forms by UV spectroscopy.Olestra: assessing its potential to interact with drugs in the gastrointestinal tract.Solid Lipid Nanoparticles of Atovaquone Based on 2(4) Full-Factorial Design.Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administrationDoes atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis?Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum.Multiple-dose, safety, pharmacokinetics, and pharmacodynamics of a new selective estrogen receptor modulator, ERA-923, in healthy postmenopausal women.Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model.SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers.Effect of dietary fat content in meals on pharmacokinetics of quazepam.The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis.Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers.Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria.Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum.A Review of Food-Drug Interactions on Oral Drug Absorption.Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement.Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii.
P2860
Q28365205-AB2AB362-7450-4304-9187-EE390E2A1F02Q33497387-2A323814-A0BA-4144-9CA7-67530B402E29Q33622892-7E03D97E-766D-4F1A-9A87-BD96C02F1008Q33836733-874C03A3-5988-4607-9549-BD62FC673BE4Q34107885-645AE8B7-0227-4AD2-B02F-F12890C2BDD8Q34778043-0DF32CC3-28B6-4C91-9AD1-D9B5A344B8B5Q35131253-C9C41DE0-D6CE-43CB-88BB-35DD029DEBF3Q35191426-F4F948DA-1CC4-43B6-99B7-CFA234395933Q35827737-F4F67526-B5DC-4415-AD49-3C17A8C17661Q36185602-22D3AE16-37BB-43F8-ADEB-F0582A4D36ECQ36482878-11A4C0E7-261D-4957-8435-323E92092E8DQ36905168-EE5BFAF8-995E-40FC-B951-C1818FBE16A3Q36945007-3B0951F9-B0B8-49B8-AE95-9BEFBBD5118EQ37055903-05F75F2F-EF5E-43FE-AD32-A6529A4E0F53Q37625142-3D7E170F-E9ED-418B-A917-B96DFC42236FQ38761368-2A02668A-53CF-490F-8F81-CCEA155F35E7Q39781539-220C1563-3225-4921-8323-08ED60FD6936Q39784345-14F15321-FCA8-40F7-BB67-685161F1A8D4Q40431023-A5695DFC-24A1-4305-848D-2DCB2FCD1EADQ40829190-C653A468-D6E0-4E38-8A52-D3390512605CQ41519239-29C36721-46B5-4F76-B77A-044520A17C2DQ42087508-C37E5015-BBB4-45E8-8114-E400F98AD905Q42565032-26D81321-2F29-4082-8084-C3463A5D3CC1Q43076540-1202ACB7-C823-478C-AB2C-4BA79A1333EAQ43801610-AF792125-A1A6-48CD-BBBB-152CDE8A15B6Q43878859-ED907678-6D22-450A-B460-AFA74AE17975Q44160872-E46B2546-B7CF-4271-B539-424DFFA2FD2AQ44164523-7CC970A0-AF02-4976-A6C7-16891A8CD158Q44237124-2C6A0CBE-4892-48B9-ADC7-2536651E7448Q46102626-F85A66C4-4808-4AEC-8D8A-29697491452EQ46828749-A52BDB90-F937-4041-A5F1-BE3853FFC064Q48026045-E473ED24-1388-4EB2-B39A-2FEBC91C0414Q48036778-4C36F0DD-D8D3-4B9B-81CF-3C1F1433D509Q48117745-3CA70355-F9EF-44E4-B0F1-455F331A8634Q51567230-D18A90A1-0AD4-461E-BF09-6FF9DBF57D24Q54432895-6FCDDAD7-D527-40BE-8739-CF214D5A6A2B
P2860
Examination of some factors responsible for a food-induced increase in absorption of atovaquone.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Examination of some factors re ...... e in absorption of atovaquone.
@en
type
label
Examination of some factors re ...... e in absorption of atovaquone.
@en
prefLabel
Examination of some factors re ...... e in absorption of atovaquone.
@en
P2093
P2860
P1476
Examination of some factors re ...... e in absorption of atovaquone.
@en
P2093
Weatherley BC
P2860
P356
10.1111/J.1365-2125.1994.TB04232.X
P407
P577
1994-01-01T00:00:00Z